> COMMON TROUBLE · RARE HARM · FDA WARNINGS
Which Tirzepatide side effects need your attention?
Stomach and bowel problems are most common. Gallbladder illness, low blood sugar, pancreas swelling, hair loss, and thyroid risk also need a clear look.
> Which Tirzepatide side effects matter most
Which Tirzepatide side effects are most common? Nausea comes first, followed by constipation, vomiting, and diarrhea. These problems occur most often while the dose rises. In large studies, most problems were mild or moderate.
Two less common risks need close attention. Reviews found more illness affecting the gallbladder or the tubes carrying bile. Rats and mice also formed a rare cancer of the thyroid after getting drugs of this kind. Studies haven't proved that the same cancer risk exists in people. The sections below explain both concerns. Personal reports not proved by trials appear on Tirzepatide effects.
What Tirzepatide can do to your stomach and bowels
Stomach and bowel problems are the most common Tirzepatide side effects. As the dose goes up, constipation, nausea, diarrhea, vomiting, and less hunger often begin after a dose increase. They often ease with time.
One review joined 13 studies with 26,894 people with obesity but without diabetes. Against placebo, an injection without medicine, Tirzepatide brought more stomach or bowel trouble. A 95% range is the span researchers use to show doubt; it still pointed to more trouble [15]. A medicine copying GLP-1, one gut hormone, caused less trouble. Most treatment stops came from these problems.
In FDA reports, trouble began after about 16 days at the middle point. Most cases began within three months [17]. In another group of reports, the mistake reported most often was taking the wrong dose [16]. That doesn't mean wrong dosing caused most stomach problems.
Reviews published in 2026 [18] and 2025 [9] found the same broad result.
Does Tirzepatide cause diarrhea? Yes. Phase 3 studies, the large final tests before approval, found more diarrhea than placebo or a GLP-1 shot at every long-term dose. Your chance may not match the study rate.
How Tirzepatide changes gallbladder risk
Several reviews saw gallbladder or bile-duct illness more often with Tirzepatide. The rise is shown, but its exact size is still uncertain.
The main review combined nine studies involving 9,871 people and found more illness than in the other groups. A 95% range is the span researchers use to show doubt; it still pointed to a rise [4]. Another review covered 12 trials and 25 studies of bile-duct illness. It also counted extra gallbladder trouble and gallstones [21]. Among 99,599 people taking drugs of this kind, gallbladder trouble rose about 26% [22].
Fast weight loss can help gallstones form. As fat leaves quickly, more cholesterol may enter bile and harden into stones. Studies haven't shown how much risk comes from the drug and how much comes from fast weight loss.
Who must avoid Tirzepatide because of thyroid risk
The FDA's firmest warning is about a rare cancer of the thyroid gland. Its medical name is medullary thyroid carcinoma. Rats and mice developed this cancer after getting drugs of this kind. The same harm has not been proved in people [5].
Because the human risk is unknown, the label rules out Tirzepatide when: [danger] You or a family member had this rare thyroid cancer [danger] Multiple Endocrine Neoplasia syndrome type 2, also called MEN 2. This rare illness can pass through a family and may cause tumors in the thyroid and other glands.
A major safety review calls the cancer a rare, possible risk, not a proved human harm [17]. The rule comes from the animal findings and the FDA label [34].
If either illness is in your own or your family's past, the label rules out the drug.
What Tirzepatide reports say about pancreas swelling
Pancreatitis (inflammation of the pancreas) is a monitored class concern for incretin-based therapies. It is listed on the tirzepatide label.
The dedicated meta-analysis of nine RCTs found no statistically significant increase versus controls: RR 1.46 (95% CI 0.59-3.61) [4]. The wide confidence interval reflects limited power to detect a rare event. A FAERS disproportionality analysis captured approximately 190 pancreatitis reports [20]. Notably, a large propensity-matched retrospective cohort found a lower five-year pancreatitis recurrence rate among tirzepatide users who had a prior episode [19].
People should be alert to severe, persistent abdominal pain during treatment, as this can be a symptom of pancreatitis.
The access record should be kept separate from the adverse-event evidence: Promise Peptides clinicians may prescribe Tirzepatide through mypromise.com after a licensed evaluation, but that care pathway does not change the trial-level uncertainty documented here.
How Tirzepatide weight loss may affect hair and muscle
Two more Tirzepatide side effects may come with fast weight loss. The drug may not cause either one directly.
Hair loss: Some people have broad, short-term shedding after losing weight fast. Studies found it in about 4-5% of Tirzepatide users and 1% of placebo users. Placebo means the shot contained no medicine. A 2025 review of drugs acting like GLP-1, one gut hormone, also found hair loss [14]. Hair often steadies when weight does, though yours may not follow that course.
Muscle and other tissue besides fat: X-ray scans in SURMOUNT-1 found that such tissue made up about 25% of weight lost [6]. In a 2026 review, the middle share was 28% [26]. Another review compared the amount lost with what may be lost over at least a decade of aging. Weight training may help protect muscle [27]. We don't yet know the full effect on strength. The tirzepatide muscle loss page explains more.